The selective tyrosine kinase inhibitors (TKI), which target the ATP binding site of BCR/ABL, block BCR/ABL kinase activity and exhibit a positive therapeutic effect for CML (10,11). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.